Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Background: Extremes of body weight may alter exposure to non-vitamin K antagonist oral
anticoagulants and thereby impact clinical outcomes. This ETNA-AF-Europe sub-analysis …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …

Abstract Purpose Direct oral anticoagulants (DOACs) are recommended in preference to
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …

Background Low-dose direct oral anticoagulant (DOAC) use is quite prevalent in clinical
practice, but evidence of its effectiveness and safety compared with high-dose DOAC in …

Aims This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

Objective To investigate the association between body mass index (BMI) and oral
anticoagulant (OAC) prescription in atrial fibrillation (AF). Methods Patients with newly …